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Recent developments in diagnostic imaging techniques have magniﬁed the role and potential of both MRI and PET-CT in female
pelvic imaging. This article reviews the techniques and clinical applications of new functional MRI (fMRI) including diﬀusion-
weighted MRI (DWI), dynamic contrast-enhanced (DCE)-MRI, comparing with PET-CT. These new emerging provide not only
anatomic but also functional imaging, allowing detection of small volumes of active tumor at diagnosis and early disease relapse,
which may not result in detectable morphological changes at conventional imaging. This information is useful in distinguishing
between recurrent/residual tumor and post-treatment changes and assessing treatment response, with a clear impact on patient
management.BothPET-CTandnowfMRIhaveprovedtobeveryvaluabletoolsforevaluationofgynecologictumors.Mostpapers
tryto comparethesetechniques, but inour experience both arecomplementary in management of thesepatients. Meanwhile PET-
CT is superior in diagnosis of ganglionar disease; fMRI presents higher accuracy in local preoperative staging. Both techniques can
be used as biomarkers of tumor response and present high accuracy in diagnosis of local recurrence and peritoneal dissemination,
with complementary roles depending on histological type, anatomic location and tumoral volume.
1.Introduction
The principal aim of oncological imaging is to diﬀerentiate
between malignant and nonmalignant tissues at all stages
of the patient’s cancer care. Accurate staging and precise
delineation of the extent of malignancy inﬂuence therapeutic
decisions, therapy outcomes, and, ultimately, patient prog-
nosis.
Conventional imaging using ultrasound, computed to-
mography (CT), or magnetic resonance imaging (MRI)
detects cancer by identifying anatomical distortion or al-
tered tissue appearances. Tumor tissue conspicuity may be
increased after the administration of intravenous contrast
medium, thus enhancing detection and delineation. How-
ever, identiﬁcation of small volume active tumor, either
at presentation or at early disease relapse remains chal-
lenging because a small volume of disease may not re-
sult in detectable structural or morphological changes on
conventional imaging. Furthermore, the eﬀects of therapy
may obscure or mimic recurrent disease.
The use of functional imaging techniques using MRI
and positron emission tomography (PET) in the evaluation
of tumors is increasing. These techniques exploit particular
pathophysiological changes occurring within tumors as their
contrast mechanism, such as altered blood ﬂow, increased
glucose metabolism, and cellularity. Therefore, functional
techniques are increasingly being used for tumor detection,
monitoring of treatment response, and detection of relapsed
disease.
2.PET-CT
PET imaging for oncology has tremendously advanced
over the past 10–15 years. The most commonly employed
radioisotope for PET imaging is 18-ﬂuorodeoxyglucose
(FDG). FDG is a glucose analogue and is injected into
the patient, then transported across the cell membrane of
actively metabolizing cells. Tumors that are visualized by
FDG-PET imaging have glucose metabolic rates that are
greater than surrounding normal cells. The standardised2 Radiology Research and Practice
uptakevalue(SUV)representsasemiquantitativeassessment
of uptake in a tumor region of interest.
FDG is not, however, entirely speciﬁc for malignant
cells, and there are a number of pitfalls when using this ra-
diotracer. On the one hand, physiological uptake occurs
in metabolically active normal tissues (i.e., brain, bowel,
genitourinary tract, salivary glands, etc.). In premenopausal
women, the uterus will often demonstrate FDG uptake most
commonly during the menstrual ﬂow phase [1]. Also in
premenopausal women an ovarian uptake of FDG can be
detected, which may be due to normal physiologic uptake
or due to malignancy. In postmenopausal women, however,
increased ovarian FDG uptake is highly associated with
malignant processes. The urinary tract and urinary bladder
will demonstrate FDG activity because FDG is eliminated
in the urine and FDG bladder activity can obscure pelvic
ﬁndings in these patients. Also focal areas of ureteral activity
can mimic nodal disease. On the other hand, benign pro-
cesses such as endometriosis, leiomyomata, inﬂammation,
and infection can all be the causes of nonmalignant FDG
uptake. Reactive lymph nodes can also be FDG avid. False
negatives can also occur, as adenocarcinomas that have a
low FDG uptake and may not be detected [2] and necrotic
lymph nodes may not be FDG avid. FDG-PET/CT is limited
in its ability to identify lesions <1cm, in particular, those
smaller than 5mm, leading to a false-negative rate of 5%–
10% [3]. Similarly, in recurrent cancer, PET-CT is somewhat
limited in its ability to distinguish early postoperative in-
ﬂammatory changes from tumor recurrence or persistence,
butcorrelationwithCTﬁndingsandthepatient’shistoryand
examination helps to determine the signiﬁcance and thus
guide management.
The utility of FDG-PET imaging for patients with gy-
necologic cancers is an ongoing process. Most of the work
in this area has been performed in patients with cervical and
ovarian cancer [1]. FDG-PET is a quite accurate method for
the detection of lymph node invasion with a sensitivity and
speciﬁcity of 100% and 99.6%, respectively, in the detection
of aﬀected lymph nodes greater than 5mm [1]. These values
decrease in nodes smaller than 5mm.
3. Diffusion-WeightedMRI (DWI)
MRI is the imagine technique with highest contrast and
anatomic resolution, being the modality of choice for
morphological evaluation of female pelvis disease. A new
emerging functional technique that is currently ﬁnding a
role in cancer imaging is DWI, which provides information
about tissue cellularity and integrity of cellular membranes.
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with relative ease employing short exploration time (about
3 or 4 minutes) and does not need for contrast medium
administration.
Atafundamentallevel,DWIprovidesinformationonthe
random (Brownian) motion of water molecules in tissues.
By comparing diﬀerences in the apparent diﬀusion between
tissues, tissue characterization becomes possible. For exam-
ple, a tumor would exhibit a more restricted diﬀusion if
compared with a cyst because intact cellular membranes in
a tumor would hinder the free movement of water molecules
[4]. Diﬀusion is quantiﬁed by a parameter, the apparent
diﬀusion coeﬃcient (ADC; unit mm2/s), which is usually
presented as a quantitative parametric map as gray-scale
images. On ADC maps, tumors usually demonstrate low
ADCvaluesandappearaslowsignalintensityareacompared
with normal tissue (Figure 1). The quantitative ADC values
can aid in lesion characterization, and can also be applied to
evaluate treatment response of tumors [5].
There are some pitfalls in the use of DWI and ADC
values. In malignant tumors with low cellularity (e.g., well-
diﬀerentiatedadenocarcinomasorovariancancerswithlarge
cystic components), or in poorly diﬀerentiated necrotic
tumors, restriction to water diﬀusion is likely to be much
more limited and may not be visible at DWI [5]. Because
of that, DWI is not useful for characterization of ovarian
lesions.
False positives can also occur. Normal endometrium and
o t h e rn o r m a ls t r u c t u r e sa sr e a c t i v el y m p hn o d e sa n db o w e l
mucosa with high cellular density are also hyperintense on
DWI. However, quantitative discrimination between normal
endometrium and cancer is most often possible due to the
signiﬁcantly lower ADC value of the tumor.
Another limitation of DWI is the presence of suppression
of background body signals, resulting in a lack of suﬃcient
anatomical information. Readers should also be aware of the
conceptofT2shine-through.Thisreferstohyperintensityon
T2-WI inﬂuencing the DWI, which is seen as high signal on
DWI, along with a bright area on the ADC map. It highlights
the need to assess the DWI in correlation with the ADC map
[5]. Due to these factors, ADC maps and DWI should never
be interpreted separately, but together with anatomic images
according to Figure 1. Fusion imaging between DWI and T2-
WI in patients with gynecological cancer is able to depict
both malignant tumors and anatomical information.
Because DWI is an emerging technique, there are few
studies on the utility of DWI for gynecological imaging.
Thus, further prospective study using larger numbers of
patients and long-term followup is needed to establish the
potential ability of DWI for gynecological diseases. Besides,
there is a lack of standardization regarding the use of
DWI in the assessment of gynecological tumors, including
diﬀerences in the ADC values of similar diseases reported
because of the use of diﬀerent techniques [4]. Clearly, future
standardization of protocols for both image acquisition and
data analysis across imaging platforms is an important item.
4. DynamicContrast-Enhanced-(DCE-)MRI
DCE-MRI involves the acquisition of sequential images
during the passage of a contrast agent through a partic-
ular tissue of interest. Dynamic imaging can depict the
distribution of this agent by measuring variations in vessel
and tissue enhancement over time. Moreover, the intensity
of the enhancement has been shown to be related to the
vascular density within tissue, while the rate and wash-
out of enhancement is related to angiogenic factors such asRadiology Research and Practice 3
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Figure 1: Synchronic ovarian serous cystadenocarcinoma and endometrium adenocarcinoma (stage IC) in a 60-year-old woman. (a)
Sagittal T2-WI image shows a unilocular cystic mass with solid mural nodules (black arrow) of heterogeneous hyperintensity. There is an
intermediate signal intensity mass ﬁlling the endometrial cavity (white arrow). ((b) and (c)) DWI: show high signal intensity corresponding
to mural nodules (black arrowhead) and an ill-deﬁned slightly hyperintense mass in the endometrial area (white arrowhead). ((d) and (e))
ADC maps: depict low signal intensity in the solid mural nodules (black arrowhead), with an ADC value of 0.81 × 10−3 mm2/s, while the
cystic component presents values of 1.3 × 10−3 mm2/s. ADC value within the endometrial mass 0.79 × 10−3 mm2/s (white arrowhead). ((f)
and (g)): Postprocessed axial images, in which fusion between DWI and T2-WI is obtained. Low ADC areas are represented in red.
microvessel density (MVD) and vascular endothelial growth
factor (VEGF) [6–8]. Variations in contrast enhancement
are associated with speciﬁc histopathological features of
the tumor [9], with more aggressive tumors commonly
exhibiting a more rapid and intense enhancement and
washout, representing a higher vascular density and strong
expression of VEGF. Therefore DCE-MRI has the ability to
noninvasively characterize tissue vasculature including the
antiangiogenic response of tumor tissue during therapeutic
intervention. By providing additional insight into tumor
perfusion and capillary permeability, this technique allows
evaluation of treatment response more readily than delayed
assessments of tumor size [10].
In gynecological oncology, DCE-MRI has been mostly
evaluatedincervicaltumors[11,12].Therearetwoinstances
in which DCE-MRI may prove useful. First, it may improve
detection of small tumors with a depth of stromal invasion
between 3 and 5mm, demonstrating a reported sensitivity
of 92% compared with 23% with T2-WI [11]. Small tumors
avidlyenhanceintheearlydynamicphaseascomparedtothe
slight enhancement of the cervical epithelium and stroma.
Second, it may help in distinguishing between recurrent
tumors and radiation ﬁbrosis [12]. It also has been studied
in the characterization of malignancy of ovarian lesions [13].
5.OvarianCancer
In the characterization of an ovarian lesion, cost-beneﬁt
studies and net cost analysis have shown that the use of MR
imaging in the evaluation of sonographically indeterminate
adnexal lesions resulted in fewer surgical procedures, better
patient triage, and net cost savings [14].
Although signal intensity characteristics can be used to
narrow the diﬀerential diagnosis of an adnexal mass, no MR4 Radiology Research and Practice
speciﬁc signal characteristics for ovarian cancer are recog-
nized.Distinctionofmalignantfrombenignlesionsismainly
based on morphologic criteria (Figure 1). The presence of
papillary projections in a cystic mass is highly suggestive of
ovarian cancer. Other features suggesting malignant etiology
include necrosis, vascular septations thicker than 3mm,
septal nodularity, and single or multiple enhancing solid
components within a cystic mass [15]. In patients with
clinically or sonographically detected complex adnexal
masses,MRimagingwasshowntohave91%accuracyforthe
diagnosis of malignancy. Ancillary ﬁndings, such as ascites,
peritonealdisease,oradenopathy,werethemostsigniﬁcantly
factors indicative of malignancy.
Functional imaging has been investigated for the detec-
tion and characterization of primary ovarian masses. Al-
though FDG avid ovarian lesions in postmenopausal women
are considered suspicious for malignancy, PET-CT is not
recommended for primary cancer detection because of
high false-positive rates. Physiologic ovarian uptake of FDG
during diﬀerent phases of the menstrual cycle [1]m a yb e
a limitation for detection of ovarian cancer. In addiction
a variety of benign lesions, such as serous and mucinous
cystadenomas, corpus luteum cysts, and dermoid cysts,
are known to accumulate FDG and may contribute to
false-positive results. Therefore, diﬀerentiating benign from
malignant lesions using PET scans alone is impossible. The
distinctiongenerallyrequirescorrelationwithadetailedclin-
ical history and morphologic imaging such as ultrasound,
CT, or MRI [16].
There are also several reports in literature about the
clinical application of DWI to characterize ovarian tumors
[17–19]. These studies show that, although ADC may help
to diﬀerentiate between normal and cancerous tissue in the
uterine cervix and endometrium (Figure 1), its usefulness
may be limited in the case of ovarian lesions, a phenomenon
attributable to their morphologic variety. Ovarian cysts
containing blood (endometrial cysts), fat (teratomas), or
pus (abscesses) present with higher water restriction and
lower ADC values lower than some malignant ovarian
cystic lesions. DCE-MRI can be useful in characterization of
internalarchitectureofcysticlesionsimprovingthedetection
of solid components [20]. DCE-MRI has also been shown
to correlate with tumor angiogenesis biomarkers in ovarian
cancer [13].
Regarding staging, ovarian cancer was traditionally
staged on the basis of surgery and pathologic conﬁrmation.
Surgical staging is based on the International Federation of
Obstetrics and Gynecology (FIGO) classiﬁcation system.
CT and MRI were found to be highly accurate in the
detection of inoperable tumor and the prediction of subop-
timal debulking, being the two modalities equally eﬀective
in the detection of inoperable tumor [21]. Although CT is
the primary imaging modality for staging ovarian cancer, a
Radiologic Diagnostic Oncology Group study showed that
MRI may be equal or superior to CT [15]. One advantage of
MRI is that it provides better soft tissue contrast than does
CT. Implants measuring 1cm or less are diﬃcult to detect by
CT, decreasing the sensitivity to less of 50% for such small-
volume disease [22].
An important issue for staging ovarian cancer is the
diﬀerentiation between stage III (liver surface implants) and
stage IV (hepatic parenchymal metastases) disease with a
direct impact on patient management (Figure 2). Sagittal or
coronal reformatted images in multislice CT or MRI may
assist in diﬀerentiating these two types. In the evaluation of
liverparenchymalmetastasesCTandMRIperformsimilarly;
however, MRI may be superior in the diagnosis of liver
lesions in a reexisting liver disease setting [15].
The role of functional imaging techniques has been
also explored for staging ovarian cancer. As previously
mentioned, FDG-PET is very accurate for detection and
localization of lesions to establish metastatic sites. Positive
predictive value was 93% for peritoneal disease measuring
equal or more than 5mm [3, 23]( Figure 2).
DWI clearly discriminates the abnormal signal intensity
of peritoneal dissemination from the signal arising from
surrounding organs such as the bowel. Fujii et al. [24]
showed that DWI was highly sensitive (90%) and speciﬁc
(95.5%) for the evaluation of peritoneal dissemination and
was of equal value as contrast-enhanced imaging in gyneco-
logical malignancy (Figure 2).
The followup of patients treated for ovarian cancer is
usually performed with serial measurements of CA-125 and
eitherCTscanorMRIoftheabdomenandpelvis.Ithasbeen
shown that in patients with a complete response to therapy,
three consecutive elevations in CA-125 values are associated
with a signiﬁcant risk of recurrence and may occur before
conventional imaging ﬁndings become positive [25].
As well as for staging, the functional techniques are
very useful in the assessment of recurrence, although most
studies have been conducted with FDG-PET. Second-look
laparotomy (SLL) is the most accurate way of assessing the
presence of microscopic and macroscopic disease; however,
it is an invasive procedure. The use of FDG-PET imaging
instead of SLL is reported to be feasible and cost eﬀective
[26]. FDG-PET helps localize the disease sites so that surgery
or biopsy can be better directed. This is useful in cases where
conventional imaging fails to detect recurrent disease [27].
FDG-PET may be more useful in detecting recurrence in
the setting of negative conventional imaging studies and an
increasing CA-125 [28]. In patients with an asymptomatic
increase of CA-125, PET has a sensitivity of 87.5%. The
combined sensitivity of PET and CA-125 is as high as 97.8%.
Another important issue of functional imaging and
speciﬁcally PET-CT include the assessment of treatment
response and prediction of treatment outcome. Avril et
al. [29] proved that sequential FDG-PET predicted patient
outcome as early as after the ﬁrst cycle of neoadju-
vant chemotherapy, being more accurate than clinical or
histopathologic response criteria, including changes in CA-
125 values.
Overall, FDG-PET [23, 26–29] and now DWI [24]h o l d
promiseintheevaluationofrecurrent/residualdiseaseandin
assessment of treatment response where other radiographic
ﬁndingsareequivocalanduncertain.Newertracersarebeing
evaluated to improve detection; however, the sensitivity to
microscopic disease is still limited.Radiology Research and Practice 5
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Figure 2: Peritoneal dissemination from recurrent ovarian serous adenocarcinoma in a 45-year-old woman. Image illustrates the diagnostic
accuracy of diﬀerent techniques. First row (a1) PET,( a 2 )CT, and (a3) DWI. Tumor deposit along the ﬁssure of the hepatoduodenal ligament
(arrows). PET and CT show only one lesion, being diﬃcult to diﬀerentiate between a hepatic deposit and peritoneal implant. At DWI, two
adjacent millimetric lesions are depicted, suggesting peritoneal implants. Second row (b1) PET,( b 2 )CT, and (b3) DWI. Implant in splenic
helium, clearly visible in PET, but hardly visible at CT. However, DWI cannot detect the lesion because of the physiological hyperintensity
of spleen. Third row (c1) PET,( c 2 )CT and (c3) DWI. A small implant in right paracolic gutter, measuring as small as 3mm. DWI clearly
demonstrates peritoneal disseminated implants as markedly hyperintense foci.
6. CervicalCancer
Staging of cervical cancer is based on clinical FIGO criteria.
Themajorlimitationsofclinicalstagingareintheassessment
of parametrial and pelvic sidewall invasion, the estimation of
tumor size (especially if the tumor is primarily endocervical
in location), and the evaluation of lymph node and distant
metastases. The accurate pretreatment evaluation of these
features is not only important for prognosis but also for
determining the appropriate mode of treatment. Evidence
shows that cross-sectional imaging is superior to clinical
staging [30].
Owing to its superior soft tissue delineation and mul-
tiplanar capability, MRI is considered the most accurate
imaging modality for the evaluation of cervical cancer, and is
nowanintegralpartoflocalstagingforpatientswithcervical
cancer. The overall staging accuracy of MRI ranges from
77 to 90% [30, 31]( Figure 3). MRI is superior to clinical
evaluation in the assessment of tumor size and provides
measurementscomparabletosurgicalmeasurementsinmost
cases [30]. The reported accuracy of MRI in the detection
of parametrial invasion ranges from 77% to 96% [30].
Because of its excellent soft-tissue resolution and the use of
endovaginal gel, MRI is advantageous in the depiction of
vaginal involvement and rectal and bladder invasion.
Although cervical cancer demonstrates variable contrast
enhancement, DCE-MRI may improve assessment of small
tumors (Figure 4). Postcontrast MRI may also help in the
detection of bladder or rectal wall invasion or delineation of
ﬁstulas.
Functional information from PET and now with DWI
and DCE-MRI can supplement morphologic information
obtainedwithconventionalcross-sectionalimagingmethods
(Figures 3, 4,a n d5). Although the current use of these
techniques in the initial evaluation of cervical cancer is
still under investigation, PET, DWI, and DCE-MRI are an
eﬀective adjunct to CT and MR imaging in evaluating
lymph node involvement, distant metastases, and treatment
response.
The use of FDG-PET is now well established in cervical
cancer, since most cervical tumors are FDG avid (Figure 3).
Adenocarcinomas, which usually have a low FDG uptake, are
an exception [2]. PET-CT can be used at the time of pre-
sentation for staging and prognostic evaluation, to monitor
response, to detect recurrence, and to plan radiotherapy.
In the context of primary tumor staging, PET-CT plays
a valuable role in the evaluation of lymph node metastases.
Nodal metastases are frequent in patients with advanced
disease (i.e., FIGO stages IIB to IVB) and FDG-PET has been
demonstrated to have a high speciﬁcity for the detection
of nodes in this group of patients [32]. FDG-PET also
improves initial staging in cases of advanced disease by
demonstrating unexpected sites of disease beyond the pelvis
orretroperitoneum,suchassupraclavicularnodalmetastases
[32].Bycontrast,thevalueofFDG-PETinearlystagedisease
(i.e., FIGO stages I to IIA) is questionable. Many studies
have reported low sensitivities for the detection of nodal
metastases, ranging from 25 to 73% [33].
As mentioned above DWI are readily usable in pelvis,
adding the possibility of discriminating between benign6 Radiology Research and Practice
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Figure 3: Stage IIb squamous cell carcinoma of the uterine cervix in a 38-year-old woman. (a) Sagittal and (b) axial T2-WI images of the
uterusshowabarrel-shapedcervical tumor(asterisks).DuetohighanatomicresolutionofMRI,axial T2-WIdemonstratesdisruptionofthe
low signal cervical stromal ring and tumoral invasion of the right parametrium (black arrow). (c) DWI: shows a well-deﬁned hyperintense
mass in the cervical area. (d) On the ADC map the tumor is hypointense and shows ADC values as low as 0.79 × 10−3 mm2/s. (e) Axial
postcontrast CT image hardly depicts cervical cancer, and is not a reliable tool for distinguishing tumor inﬁltration of adjacent parametrial
structures. (f) PET-CT: the tumor is clearly visible because of its high metabolic activity, but it is not possible to distinguish parametrial
inﬁltration.
and malignant lesions of the uterus. Cervical cancer has
shown to have signiﬁcantly lower ADC values as compared
to normal cervical tissue [34–36]. According to Tamai et
al. [35] the average median ADC of cervical cancers was
signiﬁcantly lower than normal cervix (1.09 × 10−3 versus
2.09 × 10−3 mm2/s (Figure 2)). In opposition to PET/CT,
high-grade adenocarcinomas typically have high cellular
density and so would be expected to have lower ADC values
[5].
The appropriate long-term clinical surveillance protocol
for patients with advanced cervical cancer is poorly deﬁned.
It is imperative to accurately identify those patients deemed
suitable for radical steps such as pelvic exenteration, which
is associated with considerable morbidity rates. Up to a third
of women who elected to undergo exenteration were deemed
unsuitable at the time of surgery, owing to the fact that the
extent of disease was more advanced than was despicted in
the preoperation workup [37]. On this regard, combining
functional techniques on top of conventional ones allows
detection of small volumes of active tumor, improving a
better presurgical patient selection of candidates to pelvic
exenteration.
After chemoradiation treatment, two important issues
are, in the ﬁrst place, to distinguish postradiation changes
from recurrent tumor, and in the second place, to assess
treatment response. T2-WI MRI has high sensitivity (90%-
91%) but low speciﬁcity (22%–38%) for recurrent disease
in the cervix [38]. This low speciﬁcity is caused by the
fact that benign conditions such as edema, inﬂammation,
and necrosis also may cause increased T2 signal, therefore
mimicking residual tumor.
In the context of recurrence, the applications of PET-
CT include identifying residual/recurrent disease at the
primarysite,assessmentofnodaldisease,detectionofdistant
metastases, and radiotherapy ﬁeld planning [39]. A study
found that the sensitivity of PET for detecting recurrence
was80%inasymptomaticwomenand100%insymptomatic
women [40]. FDG-PET also can be useful in women who
present with elevated markers but negative conventional
imaging, like in ovarian tumors.
PET-CT has also been proved as biomarker of tumor
response. It has been demonstrated to have a strong asso-
ciation between metabolic response and patient outcome.
Grigsby et al. [41] used pretreatment FDG-PET to evaluated
tumoral response in patients who had received nonsurgi-
cal treatment, with higher survival rates in patients who
demonstrated no residual FDG activity. FDG-PET/CT can
be utilized to outline the irradiation targets for the FDG-avid
lesions [42], and for targeting the brachytherapy portion of
the irradiation treatment [43].
DCE-MRI has been investigated in various studies as an
early indicator of tumor response to therapy and as a tool
for detecting small recurrences (Figure 4). The combination
of DCE-MRI with T2-WI improved speciﬁcity from 38%
to 67% [38] .D C E - M R Ip a r a m e t e r ss u c ha sr e l a t i v es i g n a l
intensity or peak enhancement have been investigated asRadiology Research and Practice 7
Figure 4: Proven vaginal fornix recurrence after radical surgery for cervical cancer in a 65-year-old woman. First row (a1) axial T1-WI,
(b1) DWI and (c1) PET-CT images show no remarkable alteration except for an abnormal signal at DWI in the right vaginal fornix (white
arrow), with an abnormal ADC value, measuring 1.3 ×10−3 mm2/s. Second and Third rows: six months later (a2) axial T2-WI,( b 2 )DWI,
(c2) PET-CT, and (d2) ADC map show that the ADC value in the right vaginal fornix had decreased to 1.1 ×10−3 mm2/s, corresponding
to a hypermetabolic focus at PET-CT (white arrow). (e2) and (f2) DCE-MRI depicted a small focus with faster ﬁrst-pass contrast agent
enhancement, with a type III kinetic curve (washout type), which is indicative of malignancy.
predictive markers of response even prior to the start of a
treatment regimen while changes in enhancement and signal
intensity in very early stages of therapy have been shown to
be associated with improved local tumor control [44].
DWI is now being studied in these issues. Because many
therapies induce cellular lysis, an increase in water diﬀusion
distances within tumors is expected, with increasing ADC
values following successful therapy. Naganawa et al. [45]
found signiﬁcant increases in lesion ADC values in patients
with cervical cancer who were treated with combined chem-
oradiation therapy. The success of therapy can be assessed
both quantitatively with ADC measurements and qualita-
tively by inspecting signal intensity on DWI (Figure 5).
Rapid increases in ADC values are seen following chem-
otherapy whereas changes in perfusion as depicted with
dynamic sequences have a later onset, usually occurring after
one to two cycles of chemotherapy. Radiation therapy may
also cause initially increased ADC values due to hyperemia.
Therefore,DWIandDCE-MRIarecomplementaryinassess-
ing response to therapy and should be interpreted with full
knowledge of the patient’s treatment schedule. In the same
way, hyperintense signal on DWI associated with lower ADC
values is suggestive of an active tumor [46]. Although to
date there are no publications evaluating the role of DWI
in tumoral detection; in our experience monitoring ADC
values is very useful, allowing detecting small recurrences
(Figure 4).
7.EndometrialCancer
Similar to cervical cancer, staging of endometrial cancer is
based on surgicopathologic FIGO criteria. Surgical staging,
however,isnotsuitableforwomenwhoarenotgoodsurgical
candidates because of older age, obesity, and other medical
comorbidities.
FDG-PET has been utilized in the pretreatment evalu-
ation of patients with endometrial cancer. The application
of FDG-PET/CT has been reported to improve detection of
pelvic nodal and/or soft-tissue metastases and extrapelvic
metastases [47], but little is addressed in assessing myome-
trialinvasion[48].Alsoinpremenopausalwomen,theuterus8 Radiology Research and Practice
Figure 5: Central recurrence after radical surgery for cervical cancer in a 65-year-old woman. First row (a1) and (b1) axial and sagittal
T2-WI of the uterus show a soft-tissue mass of high signal intensity in the vaginal vault. (c1) DWI shows a well-deﬁned hyperintense area
corresponding to the mass. (d1) on ADC map the tumor is hypointense (arrow). The ADC value within the mass is 0.87 × 10−3 mm2/s.
Second row six months after radiation treatment, s a gi t t a la n da x i a lT 2 - W I(a2) and (b2) show resolution of the mass. (c2) and (d2) DWI and
ADC map showed no signal intensity alteration, with an ADC value of 1.4 × 10−3 mm2/s.
Figure 6: Stage Ib endometrial cancer in a 50-year-old woman. (a) Axial T2-WI. The invasion ratio was tumor invasion depth (b) divided
by myometrial thickness (A + B) measured at DWI (b) and (a) histopathologic examination (hematoxylin-eosin stain).
will often demonstrate FDG uptake most commonly during
the menstrual ﬂow [1], not being possible to diﬀerentiate
tumoral from physiologic endometrial uptake, even with the
help of CT.
MRI is the most accurate modality for the pretreatment
evaluation of endometrial cancer. The overall staging accu-
racy of conventional MR imaging was reported to be 83%
to 92%, with 87% of sensitivity and 91% of speciﬁcity in
assessingmyometrialinﬁltration,80%ofsensitivityand96%
of speciﬁcity for cervical invasion, and 50% of sensitivity
and 95% of speciﬁcity for lymph node assessment [49]. Like
all other cross-sectional imaging methods, MR imaging isRadiology Research and Practice 9
limited in the assessment of lymph node status because it
does not allow clear diﬀerentiation between metastatic and
nonmetastatic lymph nodes of similar size. In this particular
issue FDG-PET is clearly superior.
Recent developments in functional techniques have
magniﬁed the role and potential of MRI, especially in
determining the presence of myometrial invasion. Deter-
mining the presence of myometrial invasion is a critical
factor, because the presence of deep myometrial invasion
is associated to six- to seven-fold increased prevalence of
lymph node metastases, as compared to patients with absent
or lower than 50% myometrial invasion [50]. Preoperative
determination of myometrial invasion is of great help in
determining lymphadenectomy extent.
DCE-MRIhastraditionallybeenusedbecauseT2WImay
not always appreciate the junctional zone required for deter-
mining depth of invasion, particularly in postmenopausal
patients or in patients with myometrial thinning. DCE-MRI
is especially valuable in demonstrating myometrial invasion
because the majority of tumors are hypovascular relative to
the vascular myometrium. However, a signiﬁcant number
of tumors are either iso- or hypervascular relative to the
myometrium.
Onthisregard,becauseDWIisessentiallyindependentof
diﬀerences in vascularity, it is useful for determining T stage
in such cases. Shen et al. [51] also found that DWI depicted
tumorfocithatwerenotappreciatedwithT2-WIordynamic
sequences, such as elsewhere in the uterus or in peritoneal
spread. In addition, it may not always be possible to perform
contrast-enhanced imaging due to factors such as renal
failure.Linetal.[52]foundthatfusedT2-WIandDWIat3T
have potential in the assessment of myometrial invasion in a
noninvasivemanner,withanexcellentinterreaderagreement
and a diagnostic performance as high as that of DCE-MRI
(Figure 6).
Similar to cervical cancer, the possibility of discrimi-
nating between benign and malignant lesions of the uterus
with DWI has been investigated. The ADC range of values
of endometrial cancer (0.88–0.98 × 10−3 mm2/s) is signiﬁ-
cantly lower than that of endometrial polyps (1.27–1.58 ×
10−3 mm2/s) or normal endometrium (1.53 × 10−3 mm2/s)
[51, 53]. DWI should be considered as part of routine
preoperative MRI evaluation for endometrial cancer, but
further study using larger numbers of patients and long-
term followup is needed to establish the accuracy of ADC
measurement for endometrial cancer.
8. Conclusion
The utility of FDG-PET/CT imaging for patients with gy-
necologic cancers is an ongoing process. FDG PET/CT can
signiﬁcantly assess the extent of primary and recurrent
cancer and, hence, often alters patient management. It has
high accuracy especially in the detection of nodal metastasis,
peritoneal implants less than 10mm, and small local recur-
rences. Nevertheless, because FDG PET/CT has less contrast
and anatomic resolution than MRI, it cannot replace MRI in
local preoperative staging.
DWI, a new functional MRI technique, achieves image
contrast by evaluating the random motion of water mol-
ecules within tissues. It has many advantages: the additional
scan time is relatively short and intravenous contrast is not
needed, so that it can be applied to patients with renal
impairment and integrated into routine scanning protocols.
Potential applications of fMRI and speciﬁcally DWI include
the challenging topics of distinguishing tumor from nontu-
mor tissue in cervical and endometrial cancer, presurgical
mapping, assessment of treatment response and prediction
of treatment outcome. However, DWI has a minor role in
detecting nodal metastasis.
Because DWI is an emerging technique, there are only
few studies on its applications on gynecological imaging.
In our experience, the combination of DWI with anatomic
imaging increases the diagnostic accuracy in oncologic
patients. However, further prospective study using larger
numbers of patients and long-term followup are needed
to establish the potential ability of DWI for gynecological
diseases.
Both PET-CT and now fMRI have proved to be very
valuabletoolsfortheevaluationofgynecologictumors.Most
paperstrytocomparethesetechniques,butinourexperience
they both are complementary in the management of these
patients. Meanwhile PET-CT is superior in the diagnosis of
ganglionar disease; fMRI presents higher accuracy in local
preoperative staging and distinguishing early postradiation
changes from recurrent tumor. Both techniques can be
used as biomarkers of tumor response and present high
accuracy in the diagnosis of local recurrence and peritoneal
dissemination, with complementary roles depending on
histological type, anatomic location, and tumoral volume.
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